BioNTech SE(NASDAQ : BNTX)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|REGN||Regeneron Pharmaceuticals, Inc.||-0.72%||455.31||2.7%||$529.11m|
|VRTX||Vertex Pharmaceuticals, Inc.||-1.66%||213.43||1.9%||$510.26m|
|GILD||Gilead Sciences, Inc.||-1.01%||63.07||1.0%||$495.36m|
|BNGO||BioNano Genomics, Inc.||-6.89%||10.42||0.0%||$450.76m|
|ALXN||Alexion Pharmaceuticals, Inc.||-0.15%||154.26||2.0%||$390.82m|
|CRSP||CRISPR Therapeutics AG||-2.88%||129.68||0.6%||$309.70m|
|SRNE||Sorrento Therapeutics, Inc.||-3.37%||10.60||1.3%||$256.96m|
|EXAS||EXACT Sciences Corp.||-2.87%||130.96||18.4%||$252.03m|
BioNTech SE is a next-generation immunotherapy company, which treats cancer and other serious diseases. It exploits an array of discovery and therapeutic drug platforms for the development of novel biopharmaceuticals. The company's portfolio of infectious disease and oncology product candidates include FixVac, iNeST (Individualized Neoantigen Specific Immunotherapy), Intratumoral Immunotherapies, RiboMabs, RiboCytokines, CAR T Cell Platform, T Cell Receptor(TCR), Checkpoint Immunomodulator, Targeted Cancer Antibodies, and Small Molecule Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.